Facebook      Twitter




Inflammation in Persons Living with HIV (18HH03)

Jihad Slim, MD, and Christopher F. Saling, MD

Home | Page 1 | Page 2 | Page 3 | Page 4
References | Post-Test


  1. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8:e81355. doi: 10.1371/journal. pone.0081355. eCollection 2013.
  2. Ryom L, Weber R, Morlat P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384 (9939):241-8. doi: 10.1016/ S0140-6736(14)60604-8.
  3. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28:1181–91. doi: 10.1097/ QAD.000000000000022.
  4. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53:1130–9. doi: 10.1093/ cid/cir626.Epub 2011Oct13.
  5. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120-6. doi: 10.1093/cid/ cir627. Epub 2011 Oct 13.
  6. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203. doi: 10.1371/journal.pmed.0050203.
  7. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PloS One. 2012;7: e44454. doi: 10.1371/journal.pone.0044454. Epub2012Sep10.
  8. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248-59. doi: 10.1093/infdis/jiu254.Epub2014May1.
  9. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187(10):1534-43. Epub 2003 Apr 23.
  10. Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29(4):463-71. doi: 10.1097/ QAD.0000000000000545.
  11. Tincati C, Merlini E, Braidotti P, et al. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologicallysuppressive cART. AIDS. 2016. (Epub ahead of print).
  12. Zaegel-Faucher O, Bregigeon S, Cano CE, et al. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy. AIDS. 2015;29(12):1505-10. doi: 10.1097/ QAD0000000000000650.
  13. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 2009;83(8):3719– 3733.
  14. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008;1(1): 23–30. doi: 10.1038/mi.2007.1.
  15. Ciccone EJ, Read SW, Mannon PJ, et al. Cycling of gut mucosal CD4+ T cells decreases after prolonged antiretroviral therapy and is associated with plasma LPS levels. Mucosal Immunol. 2010;3(2):172–181. doi:10.1038/ mi.2009.129Epub2009Dec2.
  16. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013;21(1):6–13. Doi: 10.1016/j. tim.2012.09.001.Epub2012Oct11.
  17. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6): 780–790. doi: 10.1093/infdis/jiq118. Epub2011Jan20.
  18. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228-38. doi: 1093/infdis/ jiu238.Epub2014Arp21
  19. Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis. 2010;10(7):455–63. doi: 10.1016/S1473- 3099(10)70093-1.
  20. Deayton JR, Sabin CA, Johnson MA, et al. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet. 2004;363(9427)2116–21.
  21. Barrett L, Fowke KR, Grant MD. Cytomegalovirus, aging, and HIV: a perfect storm. AIDS Rev. 2012;14(3):159–67.
  22. Zaegel-Faucher O, Bregigeon S, Cano CE, et al. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy AIDS. 2015;29(12):1505-10. doi: 10.1097/ QAD0000000000000650
  23. Masia M, Robledano C, Ortiz de la Tabla V, et al. Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients. PLoS One. 2014;9(8):e105442. Doi: 10.1371/journal.pone.0105442. eCollection2014.
  24. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51- 83. doi: 10.1016/B978-0-12-407707- 2.00002-3.
  25. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187(10):1534-43. Epub2003Apr23.
  26. Tincati C, Merlini E, Braidotti P, et al. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically-suppressive cART. AIDS. 2016. (Epub ahead of print).
  27. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48(6):787- 794. doi: 10.1086/597093.
  28. Engsig FN, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014;58(9):1312-1321. Doi: 10.1093/ cid/ciu038.Epub2014Jan22.
  29. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368(3):218-230. doi: 10.1056/ NEJMoa1110187.
  30. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795-807. doi: 10.1056./ NEJMoa1506816.Epub2015Jul20.
  31. Negredo E, Massanella M, Puig J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis. 2010;50(9):1300–8. doi:10.1086/651689
  32. Lapadula G, Cozzi-Lepri A, Marchetti G, et al. Risk of Clinical Progression among patients with immunological non response despite virological suppression after combination antiretroviral treatment. AIDS. 2013;27(5):769-79. Doi:10.1097/ QAD.0b013e32835cb747
  33. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155. doi:10.1146/ annurev-med-042909-093756.
  34. Leensyah E, Cameron P, Solomon A, et al. Inhibition of telomerase activity by HIV nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013;207:1157–65. doi:10.1093/ infdis/jit006.Epub2013Jan9.
  35. Freeman ML, Mudd JC, Shive CL, et al. CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ARTtreated HIV Infection. Clin Infect Dis. 2016;62(3):392-6. doi: 10.1093/cid/ civ840. Epub2015Sep 23.
  36. Erlandson KM, Allshouse AA, Jankowski CM, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208:249-59. doi: 10.1093/infdis/jit147.Epub2013Apr4.
  37. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27(6):973-9. doi: 10.1097/ QAD.0b013e32835cae9c.
  38. Aberg JA, Gallant JE, Ghanem KG., et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):e1-34. doi: 10.1093/cid/cit665. Epub2013Nov13.
  39. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614-22. doi: 10.1001/ jamainternmed.2013.3728.
  40. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-12.Epub2007Apr 24.
  41. Hsue PY, Scherzer R, Hunt PW, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc. 2012;(2).pii:jah3– e000422. doi: 10.1161/JAHA.111.000422. Epub2012Apr24.
  42. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205(Suppl 3):S375–82. doi: 10.1093/infdis/jis200.
  43. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008 13(2):177–187.
  44. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51(4):435-447. doi: 10.1086/655144.
  45. Kelesidis T, Kendall MA, Yang OO, Hodis HN. Currier J.S. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis. 2012; 206(10):1558–67. doi: 10.1093/infdis/jis545.Epub2012Oct12.
  46. Nordell AD, McKenna M, Borges AH, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014;3(3):e000844. doi: 10.1161/ JAHA.114.000844.
  47. Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335-44. doi: 10.7326/M14- 0954.
  48. Gutierrez AD, Balasubramanyam A. Dysregulation of glucose metabolisms in HIV patients: epidemiology, mechanisms, and management. Endocrine. 2012;41:1– 10. doi: 10.1007/s12020-011-9565-z.
  49. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179–93.
  50. Koethe JR, Jenkins CA, Lau B, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016;32(1):50-8. doi: 10.1089/aid.2015.0147.Epub2015Sep9.
  51. Marcus JL, Neugebauer RS, Leyden WA, et al. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals. J Acquir Immune Defic Syndr. 2016;71(4):413-9. doi: 10.1097/ QAI.0000000000000881.
  52. DAD Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs of myocardial infarction. N Engl J Med. 2007;356(17): 1723–1735.
  53. Valiathan R, Miguez MJ, Patel B, Arheart KL, Asthana D. Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot study. PLoS One. 2014;9(5):e97698. doi: 10.1371/journal.pone.0097698. eCollection2014.
  54. DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-35.
  55. Okeke NL, Hicks CB, McKellar MS, Fowler VG Jr, Federspiel JJ. History of AIDS in HIVinfected patients is associated with higher in-hospital mortality following admission for acute myocardial infarction and stroke. J Infect Dis. 2016. pii: jiw082.(Epub ahead of print).
  56. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):e29–35. doi: 10.1161/ CIRCULATIONAHA.107.189624.
  57. Giralt M, Domingo P, Villarroya F. Adipose tissue biology and HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25(3):487–99. doi: 10.1016/j. beem.2010.12.001.
  58. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev. 2008;8(1):18-23. doi: 10.1016/j. autrev.2008.07.017.Epub2008Aug15.
  59. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7. Epub2002Feb6.
  60. De Wit S, Sabin C, Weber R, et al. Data collection on adverse events of anti-HIV drugs (D:A:D) study. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) Study. Diabetes Care. 2008;31(6):1224–9. doi: 10.2337/dc07-2013. Epub2008Feb11.
  61. Betene ADC, De Wit S, Neuhaus J, et al. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy. J Acquir Immun Def Syndr. 2014;67(5):538–46. doi: 10.1097/QAI.0000000000000354.
  62. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753-62. doi: 10.1093/jnci/djr076.Epub2011Apr11.
  63. Cutrell J, Bedimo R. Non-AIDS defining cancers among HIV-infected patients. Curr HIV/AIDS Rep. 2013;10(3):207–16. Doi:10.1007/s11904-013-0166-8.
  64. Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012;24(5):506–16.
  65. Tyerman Z, Aboulafia DM. Review of screening guidelines for non-AIDS-defining malignancies: evoking issues in the era of highly active antiretroviral therapy. AIDS Rev. 2012;14(1):3–16.
  66. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884–890. Doi: 10.1200/ JCO.2008.19.6626.Epub2008Dec29.
  67. Shepherd L, Borges Á, Ledergerber B, et al. Infection-related and -unrelated malignancies, HIV and the aging population. HIV Med. 2016. doi: 10.1111/ hiv.12359.(Epub ahead of print).
  68. Riedel DJ, Tang LS, Rositch AF. The role of viral co-infection in HIV-associated non- AIDS-related cancers. Curr HIV/AIDS Rep. 2015;12(3):362-72. doi: 10.1007/s11904- 015-0276-6.
  69. Carbone A, Gloghini A, Dotti G. EBVassociated lymphoproliferative disorders: classification and treatment. Oncologist. 2008;13(5):577-85. doi: 10.1634/ theoncologist.2008-0036.
  70. Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence of HIV-related anal cancer remains increased despite longterm combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol. 2012;30(35):4360- 6. doi: 10.1200/JCO.2012.44.5486. Epub2012Oct22.
  71. Ryom L, Lundgren JD, De Wit S, et al. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS. 2016.(Epub ahead of print).
  72. Dyal HK, Aguilar M, Bartos G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: A systematic review. Dig Dis Sci. 2016;61(2):636- 45. doi: 10.1007/s10620-015-3983-3. Epub2015Dec24.
  73. Fernando SK, Finkelstein FO, Moore BA, Weissman S. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci. 2008;335(2):89-94. doi: 10.1097/ MAJ.0b013e31812e6b34.
  74. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66(3):1145-52.
  75. Abraham AG, Althoff KN, Jing Y. Endstage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60(6):941-9. doi: 10.1093/cid/ ciu919.Epub2014Nov18.
  76. Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457-68. doi: 10.2147/IJNRD.S39747.eCollection2014.
  77. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171-7. doi: 10.1038/ ki.2010.318.Epub2010Sep1.
  78. Norton BL, Park L, McGrath LJ, et al. Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. AIDS Patient Care STDS. 2012;26(9):541-5. doi: 10.1089/ apc.2012.0170.Epub2012Aug3.
  79. Towner WJ, Xu L, Leyden WA, et al. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012;60(3):321-7. doi: 10.1097/QAI.0b013e31824e9ef2.
  80. Marchetti G, Cozzi-Lepri A, Tincati C, et al. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. BMC Infect Dis. 2014;14:79. doi: 10.1186/1471- 2334-14-79.
  81. Anderson JP, Horsburgh CR Jr, Williams PL, et al. CD4 recovery on antiretroviral therapy is associated with decreased progression to liver disease among hepatitis C virus-infected injecting drug users. Open Forum Infect Dis. 2015;2(1):ofv019. doi: 10.1093/ofid/ ofv019.eCollection2015.
  82. Surgers L, Lacombe K. Hepatoxicity of new antiretrovirals: a systematic review. Clin Res Hepatol Gastroenterol. 2013;37(2):126-33. doi: 10.1016/j. clinre.2013.02.008.Epub2013 Mar21.
  83. Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev. 2013;2013:493413. doi: 10.1155/2013/493413.Epub2013Jul21.
  84. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165-74.
  85. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499- 504. doi: 10.1210/jc.20080828.Epub 2008Jul1.
  86. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011;57(3):205-210. Doi: 10.1097/QAI.0b013e31821ecf4c.
  87. Ofotokun I, McIntosh E, Weitzmann MN. HIV: inflammation and bone. Curr HIV AIDS Rep. 2012;9:16–25.
  88. Klassen KM, Fairley CK, Kimlin MG, et al. Vitamin D deficiency is common in HIV-infected southern Australian adults. Antivir Ther. 2015. doi: 10.3851/ IMP2983.(Epub ahead of print).
  89. Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone. 2010;46(1):13-7. doi: 10.1016/j. bone.2009.07.083.Epub 2009Aug5.
  90. Gutiérrez F, Masiá M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev. 2011;13(2):109–18.
  91. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol. 2010;67(6):699-714. doi: 10.1002/ ana.22053.
  92. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol. 2011;24(3):275-83. doi: 10.1097/WCO.0b013e32834695fb.
  93. Nemeth CL, Bekhbat M, Neigh GN. Neural effects of inflammation, cardiovascular disease, and HIV: Parallel, perpendicular, or progressive? Neuroscience. 2015;302:165-73. doi: 10.1016/j.neuroscience.2014.09.016. Epub2014Sep17.
  94. Himelhoch S, Goldberg R, Calmes C, et al. Screening for and prevalence of HIV and hepatitis C among an outpatient urban sample of people with serious mental illness and co-occuring substance abus. Community Psychol. 2011;39(2):231-239.Epub2011Feb2.
  95. Letendre S. Central nervous system complications in HIV disease: HIVassociated neurocognitive disorder Top Antivir Med. 2011;19(4):137-42.
  96. Benjamin LA, Bryer A, Emsley HC, et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11(10):878–90. doi: 10.1016/S1474-4422(12)70205-3.
  97. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7(8). pii:e1000321. doi: 10.1371/ journal.pmed.1000321.
  98. Martinez E, D’Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26(18):2315-2326. Doi: 10.1097/ QAD.0b013e328359f29c.
  99. Lake JE, McComsey GA, Hulgan T, et al. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial. HIV Med. 2014;15(7):431–41. doi: 10.1111/ hiv.12128.Epub2014Feb10.
  100. Silva EF, Charreau I, Gourmel B, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis. 2013; 208(6):892–7. doi: 10.1093/infdis/ jit280.Epub2013Jun24.
  101. Hileman CO, Kinley B, Scharen- Guivel V, et al. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitorbased initial antiretroviral therapy among HIV-infected individuals. J Infect Dis. 2015;212(3):345-54. doi: 10.1093/ infdis/jiv004.Epub2015Jan12.
  102. Calza L, Vanino E, Salvadori C, et al. Tenofovir/ emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. HIV Clin Trials. 2014;15(1):1–13. Doi: 10.1310/hct1501-1.
  103. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIVinfected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156– 64. doi: 10.1093/infdis/jiu012. Epub2014Jan9.
  104. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58(4):588- 595. doi: 10.1093/cid/cit748. Epub2013Nov18.
  105. Wooten JS, Nambi P, Gillard BK, et al. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/ HAART patients. Med Sci Sports Exerc. 2013; 45(6):1043–50. doi: 10.1249/ MSS.0b013e3182843961.
  106. Villar-Garcia J, Hernandez JJ, Guerri- Fernandez R, et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J Acquir Immun Def Syndr. 2015;68(3):256-63. doi: 10.1097/ QAI.0000000000000468.
  107. Sereti I, Estes JD, Thompson WL, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10(1):e1003890. doi: 10.1371/ journal.ppat.1003890.eCollection2014.
  108. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo. nih.gov/contentfiles/lvguidelines/ AdultandAdolescentGL.pdf. Accessed May 12, 2016.
© Copyright 2018, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy